Tesamorelin: A GHRH Analogue Explained
A research overview of Tesamorelin, a stabilized GHRH(1-44) analog: its N-terminal modification, its action at the pituitary GHRH receptor, and the stability considerations for lyophilised material.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at the N-terminus to resist rapid degradation by dipeptidyl peptidase-4 (DPP-4). Unlike exogenous growth hormone itself, Tesamorelin acts upstream at the pituitary somatotroph, stimulating endogenous GH release in a manner that preserves the body's natural pulsatile secretion pattern. This distinction — indirect, pulsatile stimulation versus direct, continuous GH exposure — is central to why Tesamorelin is used as a tool compound in GH-axis receptor research.
Mechanism: Pituitary GHRH Receptor Activation
Tesamorelin binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs, activating a Gs-protein-coupled cascade that raises intracellular cAMP and triggers GH vesicle release. Because this pathway remains subject to the hypothalamus's native negative-feedback loop — via somatostatin and IGF-1 — GH release stays pulsatile rather than sustained, which research models suggest lowers the risk of the receptor desensitization and compensatory suppression seen with continuous GH-axis stimulation.
Regulatory Position
Tesamorelin holds a marketing authorisation in some jurisdictions for a single, specific clinical indication. That authorisation applies only to the licensed medicine. Research-grade Tesamorelin is a laboratory reagent with no human-use authorisation in the UK or the UAE, and this page does not cover clinical use or outcomes.
Stability and Handling in Research Settings
Like most GHRH-class peptides, Tesamorelin is susceptible to degradation via oxidation of its methionine residue and is typically supplied lyophilized for this reason. Reconstituted solutions are commonly used within the same research session or short-term storage window at refrigerated temperatures, with long-term stock kept frozen and lyophilized until use — consistent with general peptide storage principles rather than requiring compound-specific handling beyond standard aseptic reconstitution technique.